|
Synonyms: CD37-SMIP [8] | TRU-016 | TRU016
Compound class:
Antibody
Comment: Otlertuzumab (TRU-016) is a monospecific, humanized anti-CD37 antibody-like protein that is being investigated as a clinical therapeutic for various form of lymphoma [4,6-7]. Otlertuzumab was developed using Aptevo's modular ADAPTIRTM platform.
|
| Immunopharmacology Comments |
| CD37 is an immuno-oncology target that is being evaluated for the treatment of B cell malignancies, including non-Hodgkin lymphoma, and CLL [6]. |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| non-Hodgkin lymphoma |
Disease Ontology:
DOID:0060060 OMIM: 605027 |
Phase 1 clinical candidate for NHL- see NCT00614042 and NCT01317901. | |
| B-cell lymphoma |
Disease Ontology:
DOID:707 |
Phase 1b clinical candidate for indolent B-cell small lymphocytic lymphoma. | 2 |
| Chronic lymphocytic leukemia |
Disease Ontology:
DOID:1040 OMIM: 151400 Orphanet: ORPHA67038 |
Phase 1 clinical candidate for CLL- see NCT01644253. | 1 |
